505 related articles for article (PubMed ID: 24824314)
1. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.
Friebel TM; Domchek SM; Rebbeck TR
J Natl Cancer Inst; 2014 Jun; 106(6):dju091. PubMed ID: 24824314
[TBL] [Abstract][Full Text] [Related]
2. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
[TBL] [Abstract][Full Text] [Related]
3. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Mavaddat N; Peock S; Frost D; Ellis S; Platte R; Fineberg E; Evans DG; Izatt L; Eeles RA; Adlard J; Davidson R; Eccles D; Cole T; Cook J; Brewer C; Tischkowitz M; Douglas F; Hodgson S; Walker L; Porteous ME; Morrison PJ; Side LE; Kennedy MJ; Houghton C; Donaldson A; Rogers MT; Dorkins H; Miedzybrodzka Z; Gregory H; Eason J; Barwell J; McCann E; Murray A; Antoniou AC; Easton DF;
J Natl Cancer Inst; 2013 Jun; 105(11):812-22. PubMed ID: 23628597
[TBL] [Abstract][Full Text] [Related]
4. The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis.
Eoh KJ; Park EY; Chang YJ; Ha HI; Hong J; Huang D; Nam EJ; Lim MC
Gynecol Oncol; 2021 Oct; 163(1):142-147. PubMed ID: 34304906
[TBL] [Abstract][Full Text] [Related]
5. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.
Schrijver LH; Antoniou AC; Olsson H; Mooij TM; Roos-Blom MJ; Azarang L; Adlard J; Ahmed M; Barrowdale D; Davidson R; Donaldson A; Eeles R; Evans DG; Frost D; Henderson A; Izatt L; Ong KR; Bonadona V; Coupier I; Faivre L; Fricker JP; Gesta P; van Engelen K; Jager A; Menko FH; Mourits MJE; Singer CF; Tan YY; Foretova L; Navratilova M; Schmutzler RK; Ellberg C; Gerdes AM; Caldes T; Simard J; Olah E; Jakubowska A; Rantala J; Osorio A; Hopper JL; Phillips KA; Milne RL; Beth Terry M; Noguès C; Engel C; Kast K; Goldgar DE; van Leeuwen FE; Easton DF; Andrieu N; Rookus MA;
Am J Obstet Gynecol; 2021 Jul; 225(1):51.e1-51.e17. PubMed ID: 33493488
[TBL] [Abstract][Full Text] [Related]
6. Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for
Li H; Terry MB; Antoniou AC; Phillips KA; Kast K; Mooij TM; Engel C; Noguès C; Stoppa-Lyonnet D; Lasset C; Berthet P; Mari V; Caron O; ; Barrowdale D; Frost D; Brewer C; Evans DG; Izatt L; Side L; Walker L; Tischkowitz M; Rogers MT; Porteous ME; Snape K; ; Meijers-Heijboer HEJ; Gille JJP; Blok MJ; Hoogerbrugge N; ; Daly MB; Andrulis IL; Buys SS; John EM; McLachlan SA; Friedlander M; ; Tan YY; Osorio A; Caldes T; Jakubowska A; Simard J; Singer CF; Olah E; Navratilova M; Foretova L; Gerdes AM; Roos-Blom MJ; Arver B; Olsson H; Schmutzler RK; Hopper JL; Milne RL; Easton DF; Van Leeuwen FE; Rookus MA; Andrieu N; Goldgar DE
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):368-378. PubMed ID: 31792088
[TBL] [Abstract][Full Text] [Related]
7. Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis.
Wang Y; Song Z; Zhang S; Wang X; Li P
Eur J Surg Oncol; 2022 Jun; 48(6):1209-1216. PubMed ID: 35216860
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
Rebbeck TR; Kauff ND; Domchek SM
J Natl Cancer Inst; 2009 Jan; 101(2):80-7. PubMed ID: 19141781
[TBL] [Abstract][Full Text] [Related]
9. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
Couch FJ; Gaudet MM; Antoniou AC; Ramus SJ; Kuchenbaecker KB; Soucy P; Beesley J; Chen X; Wang X; Kirchhoff T; McGuffog L; Barrowdale D; Lee A; Healey S; Sinilnikova OM; Andrulis IL; ; Ozcelik H; Mulligan AM; Thomassen M; Gerdes AM; Jensen UB; Skytte AB; Kruse TA; Caligo MA; von Wachenfeldt A; Barbany-Bustinza G; Loman N; Soller M; Ehrencrona H; Karlsson P; ; Nathanson KL; Rebbeck TR; Domchek SM; Jakubowska A; Lubinski J; Jaworska K; Durda K; Zlowocka E; Huzarski T; Byrski T; Gronwald J; Cybulski C; Górski B; Osorio A; Durán M; Tejada MI; Benitez J; Hamann U; Hogervorst FB; ; van Os TA; van Leeuwen FE; Meijers-Heijboer HE; Wijnen J; Blok MJ; Kets M; Hooning MJ; Oldenburg RA; Ausems MG; Peock S; Frost D; Ellis SD; Platte R; Fineberg E; Evans DG; Jacobs C; Eeles RA; Adlard J; Davidson R; Eccles DM; Cole T; Cook J; Paterson J; Brewer C; Douglas F; Hodgson SV; Morrison PJ; Walker L; Porteous ME; Kennedy MJ; Side LE; ; Bove B; Godwin AK; Stoppa-Lyonnet D; ; Fassy-Colcombet M; Castera L; Cornelis F; Mazoyer S; Léoné M; Boutry-Kryza N; Bressac-de Paillerets B; Caron O; Pujol P; Coupier I; Delnatte C; Akloul L; Lynch HT; Snyder CL; Buys SS; Daly MB; Terry M; Chung WK; John EM; Miron A; Southey MC; Hopper JL; Goldgar DE; Singer CF; Rappaport C; Tea MK; Fink-Retter A; Hansen TV; Nielsen FC; Arason A; Vijai J; Shah S; Sarrel K; Robson ME; Piedmonte M; Phillips K; Basil J; Rubinstein WS; Boggess J; Wakeley K; Ewart-Toland A; Montagna M; Agata S; Imyanitov EN; Isaacs C; Janavicius R; Lazaro C; Blanco I; Feliubadalo L; Brunet J; Gayther SA; Pharoah PP; Odunsi KO; Karlan BY; Walsh CS; Olah E; Teo SH; Ganz PA; Beattie MS; van Rensburg EJ; Dorfling CM; Diez O; Kwong A; Schmutzler RK; Wappenschmidt B; Engel C; Meindl A; Ditsch N; Arnold N; Heidemann S; Niederacher D; Preisler-Adams S; Gadzicki D; Varon-Mateeva R; Deissler H; Gehrig A; Sutter C; Kast K; Fiebig B; Heinritz W; Caldes T; de la Hoya M; Muranen TA; Nevanlinna H; Tischkowitz MD; Spurdle AB; Neuhausen SL; Ding YC; Lindor NM; Fredericksen Z; Pankratz VS; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Barile M; Bernard L; Viel A; Giannini G; Varesco L; Radice P; Greene MH; Mai PL; Easton DF; Chenevix-Trench G; ; Offit K; Simard J;
Cancer Epidemiol Biomarkers Prev; 2012 Apr; 21(4):645-57. PubMed ID: 22351618
[TBL] [Abstract][Full Text] [Related]
10. Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis.
van Bommel MHD; IntHout J; Veldmate G; Kets CM; de Hullu JA; van Altena AM; Harmsen MG
Hum Reprod Update; 2023 Mar; 29(2):197-217. PubMed ID: 36383189
[TBL] [Abstract][Full Text] [Related]
11. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
Metcalfe K; Lubinski J; Lynch HT; Ghadirian P; Foulkes WD; Kim-Sing C; Neuhausen S; Tung N; Rosen B; Gronwald J; Ainsworth P; Sweet K; Eisen A; Sun P; Narod SA;
J Natl Cancer Inst; 2010 Dec; 102(24):1874-8. PubMed ID: 21098759
[TBL] [Abstract][Full Text] [Related]
12. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
13. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.
Moorman PG; Havrilesky LJ; Gierisch JM; Coeytaux RR; Lowery WJ; Peragallo Urrutia R; Dinan M; McBroom AJ; Hasselblad V; Sanders GD; Myers ER
J Clin Oncol; 2013 Nov; 31(33):4188-98. PubMed ID: 24145348
[TBL] [Abstract][Full Text] [Related]
14. Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.
Schrijver LH; Mooij TM; Pijpe A; Sonke GS; Mourits MJE; Andrieu N; Antoniou AC; Easton DF; Engel C; Goldgar D; John EM; Kast K; Milne RL; Olsson H; Phillips KA; Terry MB; Hopper JL; van Leeuwen FE; Rookus MA
J Natl Cancer Inst; 2022 Apr; 114(4):540-552. PubMed ID: 35048954
[TBL] [Abstract][Full Text] [Related]
15. The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers.
Laitman Y; Kuchenbaecker KB; Rantala J; Hogervorst F; Peock S; Godwin AK; Arason A; Kirchhoff T; Offit K; Isaacs C; Schmutzler RK; Wappenschmidt B; Nevanlinna H; Chen X; Chenevix-Trench G; Healey S; Couch F; Peterlongo P; Radice P; Nathanson KL; Caligo MA; Neuhausen SL; Ganz P; Sinilnikova OM; McGuffog L; Easton DF; Antoniou AC; Wolf I; Friedman E
Breast Cancer Res Treat; 2012 Apr; 132(3):1119-26. PubMed ID: 22212556
[TBL] [Abstract][Full Text] [Related]
16. Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.
Milne RL; Antoniou AC
Endocr Relat Cancer; 2016 Oct; 23(10):T69-84. PubMed ID: 27528622
[TBL] [Abstract][Full Text] [Related]
17. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
18. Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies.
Park J; Huang D; Chang YJ; Lim MC; Myung SK
Carcinogenesis; 2022 Apr; 43(3):231-242. PubMed ID: 34958358
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.
Heemskerk-Gerritsen BA; Seynaeve C; van Asperen CJ; Ausems MG; Collée JM; van Doorn HC; Gomez Garcia EB; Kets CM; van Leeuwen FE; Meijers-Heijboer HE; Mourits MJ; van Os TA; Vasen HF; Verhoef S; Rookus MA; Hooning MJ;
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25788320
[TBL] [Abstract][Full Text] [Related]
20. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
